Delcath Systems Announces Presentation of Data at World Conference on Interventional Oncology

Company's Regional Delivery of High Dose Chemotherapy Highlighted as a Potential Alternative to Systemic Chemotherapy in Untreatable Liver Cancer

STAMFORD, Conn. --Delcath Systems, Inc. (Nasdaq:DCTH - News) today announced that James Pingpank, M.D., Surgery Branch of the National Cancer Institute (NCI), presented an abstract entitled, "Analysis of Clinical Toxicity in Patients Undergoing Percutaneous Intra-Arterial Hepatic Perfusion (PHP) with Melphalan for Unresectable Hepatic Malignancies," at the World Conference on Interventional Oncology taking place from May 14-17, 2007 in Washington, D.C.

Drawing from the results of 182 successful percutaneous hepatic perfusion treatments on 74 patients treated under a Cooperative Research and Development Agreement (CRADA) between Delcath and the NCI, Dr. Pingpank discussed the toxicity profiles, pharmacokinetic analysis and the appearance of efficacy in patients with diffuse hepatic malignancies receiving Percutaneous Hepatic Perfusion (PHP) with the Delcath System. The presentation chronicled patients whose hepatic disease was too extensive for resection, ablation, or embolization strategies. Dr. Pingpank noted that regional delivery of high dose chemotherapy is a potential alternative to systemic chemotherapy for patients with nonresectable hepatic malignancies, and offers the potential of an increased therapeutic index for cytotoxic agents such as Melphalan. These studies are testing whether PHP with Melphalan demonstrates efficacy in the treatment of liver cancer from a variety of histologies and provides evidence for this treatment as a viable investigative approach for a variety of other cytotoxic and biologic agents.

"These presentations are exciting to us as Dr. Pingpank's discussions focused on the excellent safety profile, the increased therapeutic index for cytotoxic agents such as Melphalan and the reproducible nature of Delcath Systems' procedure," commented Richard L. Taney, Delcath's President and Chief Executive Officer. "Venues such as these, before an audience of thought leaders in interventional oncology, expand the awareness of our technology among our target physician group, thus increasing potential patient referrals to our active clinical trials and setting the stage for eventual commercialization. The interest generated by these presentations at international conferences points to the growing acceptance by oncologists of regional therapy as a meaningful tool in the battle against cancer. We continue to believe that the Delcath System is the best method for the regionalized treatment of tumors in the liver and see the growing acceptance of regional therapies as confirmation of our business plan to continue development of expanded applications of our technology. We appreciate the NCI's continued enthusiasm for the Delcath PHP treatment and for presenting these very exciting results."

About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.